Johnson Matthey Expands its R&D and Scale-Up Facilities in Cambridge, UK
News Jan 21, 2016
Johnson Matthey has completed an expansion of its Cambridge, UK facilities, bringing additional process research & development services and kilo-scale manufacture to the growing site. This investment supports the use of Johnson Matthey’s world-leading catalyst and biocatalyst technology in process R&D and non-GMP production of materials for pre-clinical pharmaceutical and toxicology studies.
The expansion will accommodate teams of chemistry and biocatalysis process R&D scientists who will provide route scouting, process development, optimization and scale-up of heterogeneous, homogeneous and biocatalytic processes, as well as the non-GMP kilo-scale manufacture of APIs and intermediates.
“The completion of this investment follows our recent acquisition of pharmaceutical manufacturing capacity in Annan, Scotland and the Pharmorphix solid form sciences business based in Cambridge, UK,” said John Fowler, Division Director at Johnson Matthey Fine Chemicals. “It further supports our expanding global pharma services offering to enable our customers with the rapid development and sustainable manufacture of pharmaceuticals.”
The expanded facility includes 20 fume cupboards, two new kilo labs with capacity up to 100 L, a 20 L hastelloy pressure vessel (operating to 50 bar) and fermenters for enzyme production.
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE